Delivery Order SPE2DB20D3101-SPE2DB25FRAL2

Award Date 1/30/25
Potential Completion Date 1/31/25
Potential Value $5.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,365.64 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical commodity used for healthcare purposes. The contract has an ultimate completion date of February 5, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,167.20 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, with a completion date of January 6, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,488.59 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has a completion date of December 9, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,543.24 firm fixed-price delivery order is for the provision of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of November 20, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,583.60, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 30, 2025. The contract is not designated with a set-aside requirement, indicating open...
The federal contract award, identified as SPE2DX15D1053|SPE2DX25F6CYL, was granted to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,127.11 delivery order contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has a firm fixed price pricing type and an ultimate completion date of November 7, 2024. The contract is not...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,821.98 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product used in medical treatment. The contract has an ultimate completion date of October 17, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, SPE2DB22D1052|SPE2DB24FU9RP, is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $27,879.81, is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a prescription medication. The award has a firm fixed price and an ultimate completion date of August 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $91,225.17 Firm Fixed Price delivery order is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of March 22, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, SPE2DB22D1106|SPE2DB23FEFU6, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,333.23 Firm Fixed Price delivery order is for the provision of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, with a performance period ending on May 1, 2023. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB25FRAL2
    Delivery Order

This federal contract award, identified as SPE2DB20D3101|SPE2DB25FRAL2, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $5,167.20 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, with a completion date of January 31, 2025.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order is aligned with the broader IDC and does not have a set-aside designation, indicating open competition.

Generated 5/1/25, 9:51 AM